October 24, 2011- The recent announcement by GlaxoSmithKline of a malaria trial vaccine was met with huge buzz as health officials announced a possible large step forward in the fight against the deadly sickness. However, what has not be talked about is the possible deadly side effects that may accompany the new vaccine.
The recent African study of the trial vaccine was unveiled in Seattle at the Bill & Melinda Gates Foundation. The study says the vaccine, known as RTS,S, gives children much needed protection against malaria when they receive three doses in conjunction with other methods of disease control. Nonetheless, the findings also indicate a high risk for the vaccinated children of serious injury and even the possibility of death.
An Earthtimes report says that not until the latter part of 2014 will all the long-term secondary effects that accompany RTS,S be known. The study was published in the New England Journal of Medicine. What is alarming is close to 18% in the older group who received vaccinations suffered strong adverse reactions from the RTS,S vaccine. Within the youngest group of children, 13% received the same type of serious adverse reactions. Over 150 children from the two groups died during the study.
To date there is still little known about how fertility, immunity, body organs and neurological function are affected by the vaccine over the long term.